Intel stock spikes after report of possible US government stake
Patrick Burnett, Executive Vice President and Chief Medical (TASE:BLWV) Officer at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 3,847 shares of common stock on August 8, 2025. The shares were sold at a weighted average price of $14.0339, for a total value of $53,988. The transaction comes as InvestingPro data shows the stock trading near $14.74, with analysts maintaining a bullish outlook and setting price targets between $19 and $25.
The prices for the sales ranged from $13.992 to $14.12. Following the transaction, Burnett directly owns 108,999 shares of Arcutis Biotherapeutics. The company maintains strong financial health with a current ratio of 3.2, indicating solid liquidity, though InvestingPro analysis suggests the stock is currently trading near its Fair Value.
The sale was executed under a 10b5-1 trading plan adopted by Burnett on December 12, 2024, with a plan end date of February 27, 2026. The information comes from a Form 4 filing with the Securities and Exchange Commission. For deeper insights into insider trading patterns and comprehensive analysis, including 8 additional ProTips about ARQT, check out the full research report on InvestingPro.
In other recent news, Arcutis Biotherapeutics reported its financial results for the second quarter of 2025, exceeding analysts’ expectations in both earnings per share (EPS) and revenue. The company achieved an EPS of -$0.13, which was better than the anticipated -$0.17. Additionally, Arcutis reported revenue of $81.5 million, surpassing forecasts by 11.26%. These results mark a positive development for the company. The financial performance highlights Arcutis’s ability to exceed market expectations. Such results are often closely monitored by investors for indications of the company’s financial health. While the stock experienced a modest after-hours increase, the focus remains on the company’s impressive earnings and revenue performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.